ASX:TLXBiotechs
Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Class Action Lawsuit And Regulatory Setbacks
Telix Pharmaceuticals (ASX:TLX) is under pressure after a securities class action lawsuit, which followed an SEC subpoena and an FDA Complete Response Letter on TLX250-CDx, raising fresh questions about disclosure and manufacturing controls.
See our latest analysis for Telix Pharmaceuticals.
The legal and regulatory setbacks have coincided with a sharp shift in sentiment, with a 30 day share price return of negative 24.04% and a 1 year total shareholder return decline of 54.49%, contrasting...